Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Review

T Lymphocyte-Mediated Immune Responses to Chemical Haptens and Metal Ions: Implications for Allergic and Autoimmune Disease

Martin S.F.

Author affiliations

Clinical Research Group Allergology, Department of Dermatology, University of Freiburg, Freiburg, Germany

Related Articles for ""

Int Arch Allergy Immunol 2004;134:186–198

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Review

Received: February 02, 2004
Accepted: March 30, 2004
Published online: June 28, 2004
Issue release date: July 2004

Number of Print Pages: 13
Number of Figures: 4
Number of Tables: 0

ISSN: 1018-2438 (Print)
eISSN: 1423-0097 (Online)

For additional information: https://www.karger.com/IAA

Abstract

Chemical haptens and metal ions interact with proteins and thereby become recognizable by T and B lymphocytes. They induce the production of proinflammatory cytokines and chemokines by various cell types due to triggering of innate immune responses. This is an important prerequisite for the activation of the adaptive immune system and the development of diseases like allergic contact dermatitis and adverse drug and autoimmune reactions. Our increasing knowledge about the molecular basis of hapten and metal ion recognition by T cells and about the pathomechanisms of contact hypersensitivity and chemical-induced autoimmune reactions allows concomitant progress in the development of modern strategies for immunotherapy and will hopefully enable more specific intervention in hapten- and metal ion-induced human diseases in the future.

© 2004 S. Karger AG, Basel


References

  1. Garboczi DN, Biddison WE: Shapes of MHC restriction. Immunity 1999;10:1–7.
  2. Garcia KC, Teyton L, Wilson IA: Structural basis of T cell recognition. Annu Rev Immunol 1999;17:369–397.
  3. Andersen MH, Bonfill JE, Neisig A, Arsequell G, Sondergaard I, Valencia G, Neefjes J, Zeuthen J, Elliott T, Haurum JS: Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTL. J Immunol 1999;163:3812–3818.
  4. Zarling AL, Ficarro SB, White FM, Shabanowitz J, Hunt DF, Engelhard VH: Phosphorylated peptides are naturally processed and presented by major histocompatibility complex class I molecules in vivo. J Exp Med 2000;192:1755–1762.
  5. Haurum JS, Arsequell G, Lellouch AC, Wong SY, Dwek RA, McMichael AJ, Elliott T: Recognition of carbohydrate by major histocompatibility complex class I-restricted, glycopeptide-specific cytotoxic T lymphocytes. J Exp Med 1994;180:739–744.
  6. Haurum JS, Hoier IB, Arsequell G, Neisig A, Valencia G, Zeuthen J, Neefjes J, Elliott T: Presentation of cytosolic glycosylated peptides by human class I major histocompatibility complex molecules in vivo. J Exp Med 1999;190:145–150.
  7. Abdel-Motal UM, Berg L, Rosen A, Bengtsson M, Thorpe CJ, Kihlberg J, Dahmen J, Magnusson G, Karlsson KA, Jondal M: Immunization with glycosylated Kb-binding peptides generates carbohydrate-specific, unrestricted cytotoxic T cells. Eur J Immunol 1996;26:544–551.
  8. Martin S, Weltzien HU: T cell recognition of haptens, a molecular view. Int Arch Allergy Immunol 1994;104:10–16.
  9. Weltzien HU, Moulon C, Martin S, Padovan E, Hartmann U, Kohler J: T cell immune responses to haptens. Structural models for allergic and autoimmune reactions. Toxicology 1996;107:141–151.
    External Resources
  10. Martin S, Simon JC: Effector T cells and regulatory T cells in allergic contact dermatitis. Allergy Clin Immunol Intern 2001;13:117–121.
  11. Pichler WJ: Lessons from drug allergy: Against dogmata. Curr Allergy Asthma Rep 2003;3:1–3.
  12. Weltzien HU, Padovan E: Molecular features of penicillin allergy. J Invest Dermatol 1998;110:203–206.
  13. Budinger L, Hertl M: Immunologic mechanisms in hypersensitivity reactions to metal ions: An overview. Allergy 2000;55:108–115.
    External Resources
  14. Porcelli SA, Segelke BW, Sugita M, Wilson IA, Brenner MB: The CD1 family of lipid antigen-presenting molecules. Immunol Today 1998;19:362–368.
  15. Dutronc Y, Porcelli SA: The CD1 family and T cell recognition of lipid antigens. Tissue Antigens 2002;60:337–353.
  16. Landsteiner K: Die Spezifität der serologischen Reaktionen. Berlin, Springer, 1933.
  17. Landsteiner K, Chase MW: Experiments on transfer of cutaneous sensitivity to simple chemical compounds. Proc Soc Exp Biol NY 1942;49:688.
  18. Anglister J, Frey T, McConnell M: NMR technique for assessing contributions of heavy and light chains to antibody combining site. Nature 1985;315:65–67.
  19. Townsend AR, Gotch FM, Davey J: Cytotoxic T cells recognize fragments of the influenza nucleoprotein. Cell 1985;42:457–467.
  20. Ortmann B, Martin S, von Bonin A, Schiltz E, Hoschutzky H, Weltzien HU: Synthetic peptides anchor T cell-specific TNP epitopes to MHC antigens. J Immunol 1992;148:1445–1450.
  21. Falk K, Rotzschke O, Stefanovic S, Jung G, Rammensee HG: Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991;351:290–296.
  22. Martin S, Ortmann B, Pflugfelder U, Birsner U, Weltzien HU: The role of TNP-anchoring peptides in defining hapten-epitopes for MHC-restricted cytotoxic T cells: Crossreactive TNP-determinants on different peptides. J Immunol 1992;149:2569–2575.
  23. von Bonin A, Ortmann B, Martin S, Weltzien HU: Peptide-conjugated hapten groups are the major antigenic determinants for trinitrophenyl-specific cytotoxic T cells. Int Immunol 1992;4:869–874.
  24. Martin S, von Bonin A, Fessler C, Pflugfelder U, Weltzien HU: Structural complexity of antigenic determinants for class I MHC-restricted, hapten-specific T cells: Two qualitatively differing types of H-2Kb-restricted TNP epitopes. J Immunol 1993;151:678–687.
  25. Martin S, Ruh H, Hebbelmann S, Pflugfelder U, Rüde B, Weltzien HU: Carrier-reactive hapten-specific CTL clones originate from a highly preselected T cell repertoire: Implications for chemical-induced self-reactivity. Eur J Immunol 1995;25:2788–2796.
  26. Franco A, Yokoyama T, Huynh D, Thomson C, Nathenson SG, Grey HM: Fine specificity and MHC restriction of trinitrophenyl-specific CTL. J Immunol 1999;162:3388–3394.
  27. Speir JA, Abdel-Motal UM, Jondal M, Wilson IA: Crystal structure of an MHC class I presented glycopeptide that generates carbohydrate-specific CTL. Immunity 1999;10:51–61.
  28. Glithero A, Tormo J, Haurum JS, Arsequell G, Valencia G, Edwards J, Springer S, Townsend A, Pao YL, Wormald M, Dwek RA, Jones EY, Elliott T: Crystal structures of two H-2Db/glycopeptide complexes suggest a molecular basis for CTL cross-reactivity. Immunity 1999;10:63–74.
  29. Van Bleek GM, Nathenson SG: Isolation of an endogenously processed immunodominant viral peptide from the class I H-2Kb molecule. Nature 1990;348:213–216.
  30. Madden DR, Garboczi DN, Wiley DC: The antigenic identity of peptide-MHC complexes: A comparison of the conformations of five viral peptides presented by HLA-A2. Cell 1993;75:693–708.
  31. Honda S, Zhang W, Kalergis AM, DiLorenzo TP, Wang F, Nathenson SG: Hapten addition to an MHC class I-binding peptide causes substantial adjustments of the TCR structure of the responding CD8(+) T cells. J Immunol 2001;167:4276–4285.
  32. Weltzien HU, Hebbelmann S, Pflugfelder U, Ruh H, Ortmann B, Martin S, Iglesias A: Antigen contact sites in class I major histocompatibility complex-restricted, trinitrophenyl-specific T cell receptors. Eur J Immunol 1992;22:863–866.
  33. von Bonin A, Plaga S, Ruh H, Hebbelmann S, Pflugfelder U, Martin S, Weltzien HU: Analysis of major histocompatibility complex class I-restricted hapten recognition by mutation of the V-J joining of T cell receptor alpha chains. Eur J Immunol 1996;26:179–186.
  34. Kohler J, Martin S, Pflugfelder U, Ruh H, Vollmer J, Weltzien HU: Cross-reactive trinitrophenylated peptides as antigens for class II MHC-restricted T cells and inducers of contact sensitivity in mice. Limited T cell receptor repertoire. Eur J Immunol 1995;25:92–101.
  35. Kohler J, Hartmann U, Grimm R, Pflugfelder U, Weltzien HU: Carrier-independent hapten recognition and promiscuous MHC restriction by CD4 T cells induced by trinitrophenylated peptides. J Immunol 1997;158:591–597.
  36. Cavani A, Hackett CJ, Wilson KJ, Rothbard JB, Katz SI: Characterization of epitopes recognized by hapten-specific CD4+ T cells. J Immunol 1995;154:1232–1238.
  37. Martin S, Lappin MB, Kohler J, Delattre V, Leicht C, Preckel T, Simon JC, Weltzien HU: Peptide immunization indicates that CD8+ T cells are the dominant effector cells in trinitrophenyl-specific contact hypersensitivity. J Invest Dermatol 2000;115:260–266.
    External Resources
  38. Martin S, Delattre V, Leicht C, Weltzien HU, Simon JC: A high frequency of allergen-specific CD8+ Tc1 cells is associated with the murine immune response to the contact sensitizer trinitrophenyl. Exp Dermatol 2003;12:78–85.
  39. Nalefski EA, Rao A: Nature of the ligand recognized by a hapten- and carrier-specific, MHC-restricted T cell receptor. J Immunol 1993;150:3806–3816.
  40. Moulon C, Wild D, Dormoy A, Weltzien HU: MHC-dependent and -independent activation of human nickel-specific CD8+ cytotoxic T cells from allergic donors. J Invest Dermatol 1998;111:360–366.
  41. Moulon C, Choleva Y, Thierse HJ, Wild D, Weltzien HU: T cell receptor transfection shows non-HLA-restricted recognition of nickel by CD8+ human T cells to be mediated by alphabeta T cell receptors. J Invest Dermatol 2003;121:496–501.
  42. Iglesias A, Hansen-Hagge T, von Bonin A, Weltzien HU: Increased frequency of 2,4,6-trinitrophenyl (TNP)-specific, H-2b-restricted cytotoxic T lymphocyte precursors in transgenic mice expressing a T cell receptor beta chain gene from an H-2b-restricted, TNP-specific cytolytic T cell clone. Eur J Immunol 1992;22:335–341.
  43. Diamond DJ, Szalay P, Symer D, Hao P, Shin HS, Dintzis RZ, Dintzis HM, Reinherz EL, Siliciano RF: Major histocompatibility complex independent T cell receptor-antigen interaction: Functional analysis using fluorescein derivatives. J Exp Med 1991;174:229–241.
  44. Siliciano RF, Colello RM, Keegan AD, Dintzis RZ, Dintzis HM, Shin HS: Antigen valence determines the binding of nominal antigen to cytolytic T cell clones. J Exp Med 1985;162:768–773.
  45. Siliciano RF, Keegan AD, Dintzis RZ, Dintzis HM, Shin HS: The interaction of nominal antigen with T cell antigen receptors. I. Specific binding of multivalent nominal antigen to cytolytic T cell clones. J Immunol 1985;135:906–914.
  46. Stockl J, Majdic O, Fischer G, Maurer D, Knapp W: Monomorphic molecules function as additional recognition structures on haptenated target cells for HLA-A1-restricted, hapten-specific CTL. J Immunol 2001;167:2724–2733.
  47. Rao A, Ko WW, Faas SJ, Cantor H: Binding of antigen in the absence of histocompatibility proteins by arsonate-reactive T-cell clones. Cell 1984;36:879–888.
  48. Rao A, Faas SJ, Cantor H: Analogs that compete for antigen binding to an arsonate-reactive T-cell clone inhibit the functional response to arsonate. Cell 1984;36:889–895.
  49. Sato E, Hirahara K, Wada Y, Yoshitomi T, Azuma T, Matsuoka K, Kubo S, Taya C, Yonekawa H, Karasuyama H, Shiraishi A: Chronic inflammation of the skin can be induced in IgE transgenic mice by means of a single challenge of multivalent antigen. J Allergy Clin Immunol 2003;111:143–148.
  50. Fehr BS, Takashima A, Bergstresser PR, Cruz PD Jr: T cells reactive to keratinocyte antigens are generated during induction of contact hypersensitivity in mice. A model for autoeczematization in humans? Am J Contact Dermat 2000;11:145–154.
  51. Berd D: Autologous, hapten-modified vaccine as a treatment for human cancers. Vaccine 2001;19:2565–2570.
  52. Goring HD, Zierner A, Kroning Y, Trebing D, Kampgen E, Brocker EB: Effective combined immunochemotherapy with dinitrochlorobenzene and fotemustine in skin and brain metastases of melanoma. Melanoma Res 1998;8:379.
  53. Wack C, Becker JC, Brocker EB, Lutz WK, Fischer WH: Chemoimmunotherapy for melanoma with dacarbazine and 2,4-dinitrochlorobenzene: Results from a murine tumour model. Melanoma Res 2001;11:247–253.
  54. Padovan E, Bauer T, Tongio MM, Kalbacher H, Weltzien HU: Penicilloyl peptides are recognized as T cell antigenic determinants in penicillin allergy. Eur J Immunol 1997;27:1303–1307.
  55. Fontenot AP, Newman LS, Kotzin BL: Chronic beryllium disease: T cell recognition of a metal presented by HLA-DP. Clin Immunol 2001;100:4–14.
  56. Romagnoli P, Spinas GA, Sinigaglia F: Gold-specific T cells in rheumatoid arthritis patients treated with gold. J Clin Invest 1992;89:254–258.
  57. Romagnoli P, Labhardt AM, Sinigaglia F: Selective interaction of Ni with an MHC-bound peptide. EMBO J 1991;10:1303–1306.
  58. Lu L, Vollmer J, Moulon C, Weltzien HU, Marrack P, Kappler J: Components of the ligand for a Ni(++) reactive human T cell clone. J Exp Med 2003;197:567–574.
  59. Gamerdinger K, Moulon C, Karp DR, Van Bergen J, Koning F, Wild D, Pflugfelder U, Weltzien HU: A new type of metal recognition by human T cells: Contact residues for peptide-independent bridging of T cell receptor and major histocompatibility complex by nickel. J Exp Med 2003;197:1345–1353.
  60. Thierse HJ, Moulon C, Allespach Y, Zimmermann B, Doetze A, Kuppig S, Wild D, Herberg F, Weltzien HU: Metal-protein complex-mediated transport and delivery of Ni(2+) to TCR/MHC contact sites in nickel-specific human T cell activation. J Immunol 2004;172:1926–1934.
  61. Griem P, Panthel K, Kalbacher H, Gleichmann E: Alteration of a model antigen by Au(III) leads to T cell sensitization to cryptic peptides. Eur J Immunol 1996;26:279–287.
  62. Takahashi K, Kropshofer H, Vogt AB, Gleichmann E, Griem P: Drug-induced inhibition of insulin recognition by T-cells: The antirheumatic drug aurothiomalate inhibits MHC binding of insulin peptide. Mol Immunol 1998;35:1081–1087.
  63. Schnyder B, Mauri-Hellweg D, Zanni M, Bettens F, Pichler WJ: Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alphabeta T cell clones. J Clin Invest 1997;100:136–141.
  64. Zanni MP, von Greyerz S, Schnyder B, Brander KA, Frutig K, Hari Y, Valitutti S, Pichler WJ: HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human alpha beta T lymphocytes. J Clin Invest 1998;102:1591–1598.
  65. Britschgi M, von Greyerz S, Burkhart C, Pichler WJ: Molecular aspects of drug recognition by specific T cells. Curr Drug Targets 2003;4:1–11.
  66. Burkhart C, Britschgi M, Strasser I, Depta JP, von Greyerz S, Barnaba V, Pichler WJ: Non-covalent presentation of sulfamethoxazole to human CD4+ T cells is independent of distinct human leucocyte antigen-bound peptides. Clin Exp Allergy 2002;32:1635–1643.
  67. Schiffer R, Neis M, Holler D, Rodriguez F, Geier A, Gartung C, Lammert F, Dreuw A, Zwadlo-Klarwasser G, Merk H, Jugert F, Baron JM: Active influx transport is mediated by members of the organic anion transporting polypeptide family in human epidermal keratinocytes. J Invest Dermatol 2003;120:285–291.
  68. Martin S, Niedermann G, Leipner C, Eichmann K, Weltzien HU: Intracellular processing of hapten-modified protein for MHC class I presentation: Cytoplasmic delivery by pH-sensitive liposomes. Immunol Lett 1993;37:97–102.
  69. Kalish RS, Wood JA, LaPorte A: Processing of urushiol (poison ivy) hapten by both endogenous and exogenous pathways for presentation to T cells in vitro. J Clin Invest 1994;93:2039–2047.
  70. Enk AH, Katz SI: Early molecular events in the induction phase of contact sensitivity. Proc Natl Acad Sci USA 1992;89:1398–1402.
  71. Grabbe S, Schwarz T: Immunoregulatory mechanisms involved in elicitation of allergic contact hypersensitivity. Immunol Today 1998;19:37–44.
    External Resources
  72. Gautam S, Battisto J, Major JA, Armstrong D, Stoler M, Hamilton TA: Chemokine expression in trinitrochlorobenzene-mediated contact hypersensitivity. J Leukoc Biol 1994;55:452–460.
  73. Abe M, Kondo T, Xu H, Fairchild RL: Interferon-gamma inducible protein (IP-10) expression is mediated by CD8+ T cells and is regulated by CD4+ T cells during the elicitation of contact hypersensitivity. J Invest Dermatol 1996;107:360–366.
  74. Tedla N, Wang HW, McNeil HP, Di Girolamo N, Hampartzoumian T, Wakefield D, Lloyd A: Regulation of T lymphocyte trafficking into lymph nodes during an immune response by the chemokines macrophage inflammatory protein (MIP)-1 alpha and MIP-1 beta. J Immunol 1998;161:5663–5672.
  75. Sebastiani S, Albanesi C, De PO, Puddu P, Cavani A, Girolomoni G: The role of chemokines in allergic contact dermatitis. Arch Dermatol Res 2002;293:552–559.
  76. Romagnani S: Cytokines and chemoattractants in allergic inflammation. Mol Immunol 2002;38:881–885.
  77. Aiba S, Katz SI: Phenotypic and functional characteristics of in vivo-activated Langerhans cells. J Immunol 1990;145:2791–2796.
  78. Ozawa H, Nakagawa S, Tagami H, Aiba S: Interleukin-1 beta and granulocyte-macrophage colony-stimulating factor mediate Langerhans cell maturation differently. J Invest Dermatol 1996;106:441–445.
  79. Coutant KD, Ulrich P, Thomas H, Cordier A, de Fraissinette Brugerolle A: Early changes in murine epidermal cell phenotype by contact sensitizers. Toxicol Sci 1999;48:74–81.
  80. Macatonia SE, Knight SC, Edwards EJ, Griffiths S, Fryer P: Localization of antigen on lymph node dendritic cells after exposure to the contact sensitizer fluorescein isothiocyanate. Functional and morphological studies. J Exp Med 1987;166:1654–1667.
  81. Kripke ML, Munn CG, Jeevan A, Tang JM, Bucana C: Evidence that cutaneous antigen-presenting cells migrate to regional lymph nodes during contact sensitization. J Immunol 1990;145:2833–2838.
  82. Cumberbatch M, Dearman RJ, Griffiths CE, Kimber I: Langerhans cell migration. Clin Exp Dermatol 2000;25:413–418.
  83. Manome H, Aiba S, Tagami H: Simple chemicals can induce maturation and apoptosis of dendritic cells. Immunology 1999;98:481–490.
  84. Aiba S, Terunuma A, Manome H, Tagami H: Dendritic cells differently respond to haptens and irritants by their production of cytokines and expression of co-stimulatory molecules. Eur J Immunol 1997;27:3031–3038.
  85. Aiba S, Manome H, Yoshino Y, Tagami H: In vitro treatment of human transforming growth factor-beta1-treated monocyte-derived dendritic cells with haptens can induce the phenotypic and functional changes similar to epidermal Langerhans cells in the initiation phase of allergic contact sensitivity reaction. Immunology 2000;101:68–75.
  86. Arrighi JF, Rebsamen M, Rousset F, Kindler V, Hauser C: A critical role for p38 mitogen-activated protein kinase in the maturation of human blood-derived dendritic cells induced by lipopolysaccharide, TNF-alpha, and contact sensitizers. J Immunol 2001;166:3837–3845.
  87. Brand P, Plochmann S, Valk E, Zahn S, Saloga J, Knop J, Becker D: Activation and translocation of p38 mitogen-activated protein kinase after stimulation of monocytes with contact sensitizers. J Invest Dermatol 2002;119:99–106.
  88. Takanami-Ohnishi Y, Amano S, Kimura S, Asada S, Utani A, Maruyama M, Osada H, Tsunoda H, Irukayama-Tomobe Y, Goto K, Karin M, Sudo T, Kasuya Y: Essential role of p38 mitogen-activated protein kinase in contact hypersensitivity. J Biol Chem 2002;277:37896–37903.
  89. Aiba S, Manome H, Nakagawa S, Mollah ZU, Mizuashi M, Ohtani T, Yoshino Y, Tagami H: p38 Mitogen-activated protein kinase and extracellular signal-regulated kinases play distinct roles in the activation of dendritic cells by two representative haptens, NiCl2 and 2,4-dinitrochlorobenzene. J Invest Dermatol 2003;120:390–399.
  90. Matzinger P: Tolerance, danger, and the extended family. Annu Rev Immunol 1994;12:991–1045.
  91. Akira S, Takeda K, Kaisho T: Toll-like receptors: Critical proteins linking innate and acquired immunity. Nat Immunol 2001;2:675–680.
  92. Termeer C, Benedix F, Sleeman J, Fieber C, Voith U, Ahrens T, Miyake K, Freudenberg M, Galanos C, Simon JC: Oligosaccharides of Hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med 2002;195:99–111.
  93. Srivastava P: Roles of heat-shock proteins in innate and adaptive immunity. Nat Rev Immunol 2002;2:185–194.
  94. Vabulas RM, Wagner H, Schild H: Heat shock proteins as ligands of toll-like receptors. Curr Top Microbiol Immunol 2002;270:169–184.
  95. Kawai K, Shimura H, Minagawa M, Ito A, Tomiyama K, Ito M: Expression of functional Toll-like receptor 2 on human epidermal keratinocytes. J Dermatol Sci 2002;30:185–194.
  96. Song PI, Park YM, Abraham T, Harten B, Zivony A, Neparidze N, Armstrong CA, Ansel JC: Human keratinocytes express functional CD14 and toll-like receptor 4. J Invest Dermatol 2002;119:424–432.
  97. Takeuchi J, Watari E, Shinya E, Norose Y, Matsumoto M, Seya T, Sugita M, Kawana S, Takahashi H: Down-regulation of Toll-like receptor expression in monocyte-derived Langerhans cell-like cells: Implications of low-responsiveness to bacterial components in the epidermal Langerhans cells. Biochem Biophys Res Commun 2003;306:674–679.
  98. Geissmann F, Revy P, Regnault A, Lepelletier Y, Dy M, Brousse N, Amigorena S, Hermine O, Durandy A: TGF-beta 1 prevents the noncognate maturation of human dendritic Langerhans cells. J Immunol 1999;162:4567–4575.
  99. Artik S, von Vultee C, Gleichmann E, Schwarz T, Griem P: Nickel allergy in mice: Enhanced sensitization capacity of nickel at higher oxidation states. J Immunol 1999;163:1143–1152.
  100. Artik S, Haarhuis K, Wu X, Begerow J, Gleichmann E: Tolerance to nickel: Oral nickel administration induces a high frequency of anergic T cells with persistent suppressor activity. J Immunol 2001;167:6794–6803.
  101. Bos JD, Meinardi MM: The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol 2000;9:165–169.
  102. Belsito DV: The diagnostic evaluation, treatment and prevention of allergic contact dermatitis in the new millennium. J Allergy Clin Immunol 2000;105:409–420.
  103. Schnuch A, Uter W, Geier J, Gefeller O: Epidemiology of contact allergy: An estimation of morbidity employing the clinical epidemiology and drug utilization research (CE-DUR) approach. Contact Dermatitis 2002;47:32–39.
  104. Worm M: Novel therapies for atopic eczema. Curr Opin Investig Drugs 2002;3:1596–1603.
  105. Wollenberg A, Bieber T: Topical immunomodulatory agents and their targets in inflammatory skin diseases. Transplant Proc 2001;33:2212–2216.
  106. Cavani A, Albanesi C, Traidl C, Sebastiani S, Girolomoni G: Effector and regulatory T cells in allergic contact dermatitis. Trends Immunol 2001;22:118–120.
  107. Trautmann A, Akdis M, Schmid-Grendelmeier P, Disch R, Brocker EB, Blaser K, Akdis CA: Targeting keratinocyte apoptosis in the treatment of atopic dermatitis and allergic contact dermatitis. J Allergy Clin Immunol 2001;108:839–846.
  108. Fong TA, Mosmann TR: The role of IFN-gamma in delayed-type hypersensitivity mediated by Th1 clones. J Immunol 1989;143:2887–2893.
  109. Bour H, Peyron E, Gaucherand M, Garrigue JL, Desvignes C, Kaiserlian D, Revillard JP, Nicolas JF: Major histocompatibility complex class I-restricted CD8+ T cells and class II-restricted CD4+ T cells, respectively, mediate and regulate contact sensitivity to dinitrofluorobenzene. Eur J Immunol 1995;25:3006–3010.
  110. Xu H, DiIulio NA, Fairchild RL: T cell populations primed by hapten sensitization in contact sensitivity are distinguished by polarized patterns of cytokine production: Interferon gamma-producing (Tc1) effector CD8+ T cells and interleukin (Il) 4/Il-10-producing (Th2) negative regulatory CD4+ T cells. J Exp Med 1996;183:1001–1012.
  111. Kalish RS, Morimoto C: Quantitation and cloning of human urushiol specific peripheral blood T-cells: Isolation of urushiol triggered suppressor T-cells. J Invest Dermatol 1989;92:46–52.
  112. Cavani A, Mei D, Guerra E, Corinti S, Giani M, Pirrotta L, Puddu P, Girolomoni G: Patients with allergic contact dermatitis to nickel and nonallergic individuals display different nickel-specific T cell responses. Evidence for the presence of effector CD8+ and regulatory CD4+ T cells. J Invest Dermatol 1998;111:621–628.
  113. Desvignes C, Etchart N, Kehren J, Akiba I, Nicolas JF, Kaiserlian D: Oral administration of hapten inhibits in vivo induction of specific cytotoxic CD8+ T cells mediating tissue inflammation: A role for regulatory CD4+ T cells. J Immunol 2000;164:2515–2522.
  114. Cavani A, Nasorri F, Prezzi C, Sebastiani S, Albanesi C, Girolomoni G: Human CD4+ T lymphocytes with remarkable regulatory functions on dendritic cells and nickel-specific Th1 immune responses. J Invest Dermatol 2000;114:295–302.
  115. Cavani A, Nasorri F, Ottaviani C, Sebastiani S, De Pita O, Girolomoni G: Human CD25+ regulatory T cells maintain immune tolerance to nickel in healthy, nonallergic individuals. J Immunol 2003;171:5760–5768.
  116. Okazaki F, Kanzaki H, Fujii K, Arata J, Akiba H, Tsujii K, Iwatsuki K: Initial recruitment of interferon-gamma-producing CD8+ effector cells, followed by infiltration of CD4+ cells in 2,4,6-trinitro-1-chlorobenzene (TNCB)-induced murine contact hypersensitivity reactions. J Dermatol 2002;29:699–708.
  117. Asada H, Linton J, Katz SI: Cytokine gene expression during the elicitation phase of contact sensitivity: Regulation by endogenous IL-4. J Invest Dermatol 1997;108:406–411.
  118. Gorbachev AV, Fairchild RL: Regulatory role of CD4+ T cells during the development of contact hypersensitivity responses. Immunol Res 2001;24:69–77.
  119. Watanabe H, Unger M, Tuvel B, Wang B, Sauder DN: Contact hypersensitivity: The mechanism of immune responses and T cell balance. J Interferon Cytokine Res 2002;22:407–412.
  120. Kehren J, Desvignes C, Krasteva M, Ducluzeau MT, Assossou O, Horand F, Hahne M, Kägi D, Kaiserlian D, Nicolas JF: Cytotoxicity is mandatory for CD8(+) T cell-mediated contact hypersensitivity. J Exp Med 1999;189:779–786.
  121. Akiba H, Kehren J, Ducluzeau MT, Krasteva M, Horand F, Kaiserlian D, Kaneko F, Nicolas JF: Skin inflammation during contact hypersensitivity is mediated by early recruitment of CD8+ T cytotoxic 1 cells inducing keratinocyte apoptosis. J Immunol 2002;168:3079–3087.
  122. Traidl C, Sebastiani S, Albanesi C, Merk HF, Puddu P, Girolomoni G, Cavani A: Disparate cytotoxic activity of nickel-specific CD8+ and CD4+ T cell subsets against keratinocytes. J Immunol 2000;165:3058–3064.
  123. Trautmann A, Akdis M, Kleemann D, Altznauer F, Simon HU, Graeve T, Noll M, Brocker EB, Blaser K, Akdis CA: T cell-mediated Fas-induced keratinocyte apoptosis plays a key pathogenetic role in eczematous dermatitis. J Clin Invest 2000;106:25–35.
  124. Hertl M, Geisel J, Boecker C, Merk HF: Selective generation of CD8+ T-cell clones from the peripheral blood of patients with cutaneous reactions to beta-lactam antibiotics. Br J Dermatol 1993;128:619–626.
  125. Hertl M, Bohlen H, Jugert F, Boecker C, Knaup R, Merk HF: Predominance of epidermal CD8+ T lymphocytes in bullous cutaneous reactions caused by beta-lactam antibiotics. J Invest Dermatol 1993;101:794–799.
  126. Yawalkar N, Egli F, Hari Y, Nievergelt H, Braathen LR, Pichler WJ: Infiltration of cytotoxic T cells in drug-induced cutaneous eruptions. Clin Exp Allergy 2000;30:847–855.
  127. Yawalkar N, Hari Y, Frutig K, Egli F, Wendland T, Braathen LR, Pichler WJ: T cells isolated from positive epicutaneous test reactions to amoxicillin and ceftriaxone are drug specific and cytotoxic. J Invest Dermatol 2000;115:647–652.
  128. Pichler WJ, Yawalkar N: Allergic reactions to drugs: Involvement of T cells. Thorax 2000;55(suppl 2):S61–S65.
  129. Martin S, Weiss JM, Simon JC: Advances in allergy research – basic and clinical science make progress. Trends Immunol 2002;23:329–330.
  130. Shevach EM: CD4+ CD25+ suppressor T cells: More questions than answers. Nat Rev Immunol 2002;2:389–400.
  131. Bach JF: Regulatory T cells under scrutiny. Nat Rev Immunol 2003;3:189–198.
  132. Biedermann T, Mailhammer R, Mai A, Sander C, Ogilvie A, Brombacher F, Maier K, Levine AD, Rocken M: Reversal of established delayed type hypersensitivity reactions following therapy with IL-4 or antigen-specific Th2 cells. Eur J Immunol 2001;31:1582–1591.
  133. Bellinghausen I, Knop J, Saloga J: The role of interleukin 10 in the regulation of allergic immune responses. Int Arch Allergy Immunol 2001;126:97–101.
  134. Akdis CA, Blaser K: Mechanisms of interleukin-10-mediated immune suppression. Immunology 2001;103:131–136.
  135. Simon JC, Hara H, Denfeld RW, Martin S: UVB-irradiated dendritic cells induce nonproliferating, regulatory type T cells. Skin Pharmacol Appl Skin Physiol 2002;15:330–334.
  136. Schwarz T: Ultraviolet radiation-induced tolerance. Allergy 1999;54:1252–1261.
    External Resources
  137. Preckel T, Grimm R, Martin S, Weltzien HU: Altered hapten ligands antagonize trinitrophenyl-specific cytotoxic T cells and block internalization of hapten-specific receptors. J Exp Med 1997;185:1803–1813.
  138. Preckel T, Breloer M, Kohler H, von Bonin A, Weltzien HU: Partial agonism and independent modulation of T cell receptor and CD8 in hapten-specific cytotoxic T cells. Eur J Immunol 1998;28:3706–3718.
  139. Preckel T, Hellwig S, Pflugfelder U, Lappin MB, Weltzien HU: Clonal anergy induced in a CD8+ hapten-specific cytotoxic T-cell clone by an altered hapten-peptide ligand. Immunology 2001;102:8–14.
  140. Steinbrink K, Sorg C, Macher E: Low zone tolerance to contact allergens in mice: A functional role for CD8+ T helper type 2 cells. J Exp Med 1996;183:759–768.
  141. Dubois B, Chapat L, Goubier A, Papiernik M, Nicolas JF, Kaiserlian D: Innate CD4+CD25+ regulatory T cells are required for oral tolerance and inhibition of CD8+ T cells mediating skin inflammation. Blood 2003;102:3295–3301.
  142. Roelofs-Haarhuis K, Wu X, Nowak M, Fang M, Artik S, Gleichmann E: Infectious nickel tolerance: A reciprocal interplay of tolerogenic APCs and T suppressor cells that is driven by immunization. J Immunol 2003;171:2863–2872.
  143. Dudda JC, Denfeld RW, Simon JC, Martin SF: UVB-irradiated dendritic cells fail to tolerize murine CD8+ naïve or effector T cells. J Invest Dermatol 2004;122:945–952.
  144. Denfeld RW, Hara H, Tesmann JP, Martin S, Simon JC: UVB-irradiated dendritic cells are impaired in their APC function and tolerize primed Th1-cells but not naive T cells. J Leukoc Biol 2001;69:548–545.
  145. Mackay CR: Chemokines: Immunology’s high impact factors. Nat Immunol 2001;2:95–101.
  146. Campbell DJ, Kim CH, Butcher EC: Chemokines in the systemic organization of immunity. Immunol Rev 2003;195:58–71.
  147. Dudda JC, Martin SF: Tissue targeting of T cells by DCs and microenvironments. Trends Immunol 2004, in press.
  148. Stagg AJ, Kamm MA, Knight SC: Intestinal dendritic cells increase T cell expression of alpha4beta7 integrin. Eur J Immunol 2002;32:1445–1454.
  149. Svensson M, Marsal J, Ericsson A, Carramolino L, Broden T, Marquez G, Agace WW: CCL25 mediates the localization of recently activated CD8alphabeta(+) lymphocytes to the small-intestinal mucosa. J Clin Invest 2002;110:1113–1121.
  150. Mora JR, Bono MR, Manjunath N, Weninger W, Cavanagh LL, Rosemblatt M, von Andrian UH: Selective imprinting of gut-homing T cells by Peyer’s patch dendritic cells. Nature 2003;424:88–93.
  151. Johansson-Lindbom B, Svensson M, Wurbel MA, Malissen B, Marquez G, Agace WW: Selective generation of gut tropic T cells in gut-associated lymphoid tissue (GALT): Requirement for GALT dendritic cells and adjuvant. J Exp Med 2003;198:963–969.
  152. Mullins DW, Sheasley SL, Ream RM, Bullock TN, Fu YX, Engelhard VH: Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control. J Exp Med 2003;198:1023–1034.
  153. Lappin MB, Weiss JM, Delattre V, Mai B, Dittmar H, Maier C, Mahnke K, Grabbe S, Martin S, Simon JC: Analysis of mouse dendritic cell migration in vivo upon subcutaneous and intravenous injection. Immunology 1999;98:181–188.
    External Resources
  154. Dudda JC, Simon JC, Martin S: Dendritic cell immunization route determines CD8+ T cell trafficking to inflamed skin. Role for tissue microenvironment and dendritic cells in establishment of T cell homing subsets. J Immunol 2004;172:857–863.
  155. Campbell JJ, Butcher EC: Rapid acquisition of tissue-specific homing phenotypes by CD4(+) T cells activated in cutaneous or mucosal lymphoid tissues. J Exp Med 2002;195:135–141.
  156. Liu YJ, Kanzler H, Soumelis V, Gilliet M: Dendritic cell lineage, plasticity and cross-regulation. Nat Immunol 2001;2:585–589.
  157. Carballido JM: Therapeutic modification of leukocyte homing to the skin. Exp Dermatol 2002;11:485–486.
    External Resources
  158. Mackay CR: New avenues for anti-inflammatory therapy. Nat Med 2002;8:117–118.
  159. von Andrian UH, Engelhardt B: Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med 2003;348:68–72.
    External Resources
  160. Boehncke WH, Schon MP: Interfering with leukocyte rolling – a promising therapeutic approach in inflammatory skin disorders? Trends Pharmacol Sci 2003;24:49–52.
  161. Liblau RS, Wong FS, Mars LT, Santamaria P: Autoreactive CD8 T cells in organ-specific autoimmunity. Emerging targets for therapeutic intervention. Immunity 2002;17:1–6.
  162. Kalish RS, Askenase PW: Molecular mechanisms of CD8+ T cell-mediated delayed hypersensitivity: Implications for allergies, asthma, and autoimmunity. J Allergy Clin Immunol 1999;103:192–199.
  163. Dimitroff CJ, Kupper TS, Sackstein R: Prevention of leukocyte migration to inflamed skin with a novel fluorosugar modifier of cutaneous lymphocyte-associated antigen. J Clin Invest 2003;112:1008–1018.
  164. Schon MP, Krahn T, Schon M, Rodriguez ML, Antonicek H, Schultz JE, Ludwig RJ, Zollner TM, Bischoff E, Bremm KD, Schramm M, Henninger K, Kaufmann R, Gollnick HP, Parker CM, Boehncke WH: Efomycine M, a new specific inhibitor of selectin, impairs leukocyte adhesion and alleviates cutaneous inflammation. Nat Med 2002;8:366–372.
  165. Engeman TM, Gorbachev AV, Gladue RP, Heeger PS, Fairchild RL: Inhibition of functional T cell priming and contact hypersensitivity responses by treatment with anti-secondary lymphoid chemokine antibody during hapten sensitization. J Immunol 2000;164:5207–5214.
  166. Biedermann T, Schwärzler C, Lametschwandtner G, Thoma G, Carballido-Perrig N, Kund J, de Vries JE, Rot A, Carballido JM: Targeting CLA/E-selectin interactions prevents CCR4-mediated recruitment of human Th2 memory cells to human skin in vivo. Eur J Immunol 2002;32:3171–3180.
  167. Jutel M, Akdis M, Budak F, Aebischer-Casaulta C, Wrzyszcz M, Blaser K, Akdis CA: IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003;33:1205–1214.
  168. Akdis CA, Blaser K: IL-10-induced anergy in peripheral T cell and reactivation by microenvironmental cytokines: Two key steps in specific immunotherapy. FASEB J 1999;13:603–609.
  169. Erb KJ, Wohlleben G: Novel vaccines protecting against the development of allergic disorders: A double-edged sword? Curr Opin Immunol 2002;14:633–643.
  170. Lewis DB: Allergy immunotherapy and inhibition of Th2 immune responses: A sufficient strategy? Curr Opin Immunol 2002;14:644–651.
  171. Francis JN, Till SJ, Durham SR: Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol 2003;111:1255–1261.

Article / Publication Details

First-Page Preview
Abstract of Review

Received: February 02, 2004
Accepted: March 30, 2004
Published online: June 28, 2004
Issue release date: July 2004

Number of Print Pages: 13
Number of Figures: 4
Number of Tables: 0

ISSN: 1018-2438 (Print)
eISSN: 1423-0097 (Online)

For additional information: https://www.karger.com/IAA


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.